Oslo, February 17, 2014 Reference is made to the stock exchange notifications by Aqua Bio Technology ASA on February 10 and 11, 2014. Aqua Bio Technology ASA (Oslo Axess: ABT ) is a Norwegian biotechnology company that develops and markets patented ingredients and technologies for the international cosmetics industry. The company's proprietary and patented technology is based on natural proteins that exist in marine raw materials. The company has through three manufacturing processes developed three distinctly different products; Aquabeautine XL(TM), Dermaclarine(TM)and Beauty Propelline(TM). As a professional company in a competitive market, ABT has established quality processes governing product release to the market that includes specific analyses of the proteins in the respective products. These analyses are performed by scientifically qualified personnel and are validated before a product is released into the market. This validation is reflected in a Certificate of Analysis issued for each production batch and this Certificate accompanies the product delivered to ABT's customers. One of ABT's exclusivity partners for Aquabeautine XL(TM) -- Restorsea LLC -- recently filed a Complaint against ABT for breach of an exclusivity agreement dated 8 September 2012 allegedly concerning product composition. ABT has not yet received formal service of the Complaint so it is not required to respond to Restorsea's allegations in Court until that time. As noted earlier, ABT believes the lawsuit is substantively and procedurally deficient, and intends to address these shortcomings in Court at the appropriate time. Nevertheless, ABT notes that contrary to recent comments by a Restorsea executive, the parties were engaged in discussions to resolve this issue for several months before the lawsuit was filed. ABT provided detailed analyses and reports to Restorsea, confirming unequivocally that its products composition conformed to contractual requirements. ABT continues to maintain that agreement on underlying technical issues is critical to resolving the dispute. Such a resolution is best achieved outside the media or courtrooms. ABT will continue to inform the market on further developments in the case in accordance with its obligations as a listed company. For further information, please contact: Arvid Lindberg, CEO E-mail: arvid@aquabiotech.no Phone: +47 9824 5410 John Afseth, Chairman of the Board Phone: +47 92 20 18 50 About Aqua Bio Technology ASA (www.aquabiotechnology.com) Aqua Bio Technology ASA (ABT) develops, produces and markets patented ingredients and technologies to the international cosmetic and skin care industry. ABT's main ingredients Aquabeautine XL, Dermaclarine and Beauty Propelline are marine solutions derived from the hatching fluid of salmon. ABT is listed on the Oslo Stock Exchange's Axess market.
Recent Comments